Terms: = Prostate cancer AND CBLB, DKFZp686J10223, 868, ENSG00000114423, Nbla00127, RNF56, FLJ41152, FLJ36865, DKFZp779F1443, DKFZp779A0729 AND Treatment
20 results:
1. Impact of urinary diversion type on urethral recurrence following radical cystectomy for bladder cancer: propensity score matched and weighted analyses of retrospective cohort.
Yu J; Lee CU; Chung JH; Song W; Kang M; Jeon HG; Jeong BC; Seo SI; Jeon SS; Sung HH
Int J Surg; 2024 Feb; 110(2):700-708. PubMed ID: 38000052
[TBL] [Abstract] [Full Text] [Related]
2. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.
Saad F; Chilelli A; Hui B; Muratov S; Ganguli A; North S; Shayegan B
J Med Econ; 2022; 25(1):583-590. PubMed ID: 35469527
[TBL] [Abstract] [Full Text] [Related]
3. The efficacy and tolerability of ultra-hypofractionated radiotherapy in low-intermediate risk prostate cancer patients: single center experience.
Dinçer S; Uysal E; Berber T; Akboru MH
Aging Male; 2021 Dec; 24(1):50-57. PubMed ID: 34233569
[TBL] [Abstract] [Full Text] [Related]
4. Concomitant intraductal carcinoma of the prostate and response to hormonal therapy in metastatic prostate carcinoma.
Abascal-Junquera JM; Fumadó-Ciutat L; Gasa-Galmes B; Costa-Planells M; Munarriz-Polo M; Sanromà-Salvà A; Polaina-Barroso L; Solà-Marqués C; Juanpere-Rodero N; Lloreta-Trull J; Cecchini-Rosell L
Actas Urol Esp (Engl Ed); 2021; 45(6):455-460. PubMed ID: 34147428
[TBL] [Abstract] [Full Text] [Related]
5. Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
Corradi JP; Cumarasamy CW; Staff I; Tortora J; Salner A; McLaughlin T; Wagner J
Prostate; 2021 Jul; 81(10):694-702. PubMed ID: 34002865
[TBL] [Abstract] [Full Text] [Related]
6. Quality of Life After Bladder cancer: A Cross-sectional Survey of Patient-reported Outcomes.
Catto JWF; Downing A; Mason S; Wright P; Absolom K; Bottomley S; Hounsome L; Hussain S; Varughese M; Raw C; Kelly P; Glaser AW
Eur Urol; 2021 May; 79(5):621-632. PubMed ID: 33581875
[TBL] [Abstract] [Full Text] [Related]
7. Radiomics Based on MRI as a Biomarker to Guide Therapy by Predicting Upgrading of prostate cancer From Biopsy to Radical prostatectomy.
Zhang GM; Han YQ; Wei JW; Qi YF; Gu DS; Lei J; Yan WG; Xiao Y; Xue HD; Feng F; Sun H; Jin ZY; Tian J
J Magn Reson Imaging; 2020 Oct; 52(4):1239-1248. PubMed ID: 32181985
[TBL] [Abstract] [Full Text] [Related]
8. prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.
Hongo F; Okihara K; Kitamura K; Fujihara A; Yamada Y; Shiraishi T; Konishi E; Ukimura O
Int J Urol; 2019 Aug; 26(8):827-832. PubMed ID: 31183899
[TBL] [Abstract] [Full Text] [Related]
9. Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity.
Franzese C; D'agostino G; Di Brina L; Navarria P; De Rose F; Comito T; Franceschini D; Mancosu P; Tomatis S; Scorsetti M
Br J Radiol; 2019 May; 92(1097):20190021. PubMed ID: 30864833
[TBL] [Abstract] [Full Text] [Related]
10. Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.
Kang YJ; Jang WS; Kwon JK; Yoon CY; Lee JY; Ham WS; Choi YD
BMC Cancer; 2017 Nov; 17(1):789. PubMed ID: 29169347
[TBL] [Abstract] [Full Text] [Related]
11. Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies.
Osman MH; Farrag E; Selim M; Osman MS; Hasanine A; Selim A
PLoS One; 2017; 12(6):e0178611. PubMed ID: 28591151
[TBL] [Abstract] [Full Text] [Related]
12. A comparative analysis of complications after robot-assisted radical prostatectomy for men aged ≤69 and ≥70 years.
Babaian KN; Skarecky D; Liss MA; Osann K; Lusch A; Ahlering TE
J Endourol; 2014 Dec; 28(12):1435-8. PubMed ID: 25211698
[TBL] [Abstract] [Full Text] [Related]
13. Concomitant high-grade prostatic intraepithelial neoplasia is associated with good prognosis factors and oncologic outcome after radical prostatectomy.
Ingels A; Ploussard G; Allory Y; Abbou C; de la Taille A; Salomon L
Urol Int; 2014; 92(3):264-9. PubMed ID: 23919964
[TBL] [Abstract] [Full Text] [Related]
14. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
Shteynshlyuger A; Andriole GL
J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
[TBL] [Abstract] [Full Text] [Related]
15. Development of a comorbidity index using physician claims data.
Klabunde CN; Potosky AL; Legler JM; Warren JL
J Clin Epidemiol; 2000 Dec; 53(12):1258-67. PubMed ID: 11146273
[TBL] [Abstract] [Full Text] [Related]
16. Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy.
Kao TC; Cruess DF; Garner D; Foley J; Seay T; Friedrichs P; Thrasher JB; Mooneyhan RD; McLeod DG; Moul JW
J Urol; 2000 Mar; 163(3):858-64. PubMed ID: 10687992
[TBL] [Abstract] [Full Text] [Related]
17. Assessment of the micronucleus assay as a biological dosimeter using cytokinesis-blocked lymphocytes from cancer patients receiving fractionated partial body-radiotherapy.
le Roux J; Slabbert J; Smit B; Blekkenhorst G
Strahlenther Onkol; 1998 Feb; 174(2):75-81. PubMed ID: 9487369
[TBL] [Abstract] [Full Text] [Related]
18. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract] [Full Text] [Related]
19. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Berrevoets CA; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
[TBL] [Abstract] [Full Text] [Related]
20. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
[TBL] [Abstract] [Full Text] [Related]
